NASDAQ:ACER - Acer Therapeutics Stock Price, Price Target & More

Acer Therapeutics trades on the NASDAQ under the ticker symbol "ACER."

Acer Therapeutics Inc (NASDAQ:ACER) posted its quarterly earnings results on Monday, May, 14th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.69) by $0.16. View Acer Therapeutics' Earnings History.

4 equities research analysts have issued 12-month price targets for Acer Therapeutics' shares. Their forecasts range from $28.00 to $70.00. On average, they anticipate Acer Therapeutics' stock price to reach $49.3333 in the next twelve months. This suggests a possible upside of 127.0% from the stock's current price. View Analyst Ratings for Acer Therapeutics.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acer Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Acer Therapeutics include GlycoMimetics (GLYC), Abeona Therapeutics (ABEO), Vectura Group (VEGPF), Urogen Pharma (URGN), Kura Oncology (KURA), Viking Therapeutics (VKTX), Collegium Pharmaceutical (COLL), Dova Pharmaceuticals (DOVA), Odonate Therapeutics (ODT), Aclaris Therapeutics (ACRS), Dicerna Pharmaceuticals (DRNA), ChemoCentryx (CCXI), Progenics Pharmaceuticals (PGNX), Five Prime Therapeutics (FPRX) and Arbutus Biopharma (ABUS).

Media coverage about ACER stock has been trending somewhat negative this week, according to Accern Sentiment Analysis. Accern scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Acer Therapeutics earned a news sentiment score of -0.02 on Accern's scale. They also gave media headlines about the biopharmaceutical company an impact score of 45.24 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Shares of ACER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ACER stock can currently be purchased for approximately $21.73.

Acer Therapeutics has a market capitalization of $169.03 million and generates $2.90 million in revenue each year. The biopharmaceutical company earns $-14,190,000.00 in net income (profit) each year or ($3.84) on an earnings per share basis. Acer Therapeutics employs 6 workers across the globe.

Acer Therapeutics' mailing address is 300 WASHINGTON STREET SUITE 351, NEWTON MA, 02458. The biopharmaceutical company can be reached via phone at 844-902-6100 or via email at [email protected]